Developmental and Epileptic Encephalopathies Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies and Companies by DelveInsight

Developmental and Epileptic Encephalopathy companies Takeda, Eisai, SK Life Science, Stoke Therapeutics, Harmony Biosciences/Epygenix, Longboard Pharmaceuticals, Praxis Precision Medicines, Neurocrine Biosciences, Bright Minds Biosciences, Cerecin, Encoded Therapeutics, Bloom Science, Neuroene Therapeutics, Regel Therapeutics, Jazz Pharmaceuticals, Biocodex, Zogenix, Lundbeck, Marinus Pharmaceuticals, Novartis, Eisai Pharmaceuticals, GlaxoSmithKline, Roche, others.
(Albany, USA) DelveInsight's Developmental and Epileptic Encephalopathy Market Insights report includes a comprehensive understanding of current treatment practices, developmental and epileptic encephalopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Developmental and Epileptic Encephalopathy Market Report

* As per DelveInsight analysis, the developmental and epileptic encephalopathy market size in the 7MM was approximately USD 2100 million in 2023.
* According to the assessment done by DelveInsight, the estimated total DEE diagnosed prevalent cases in the 7MM were approximately 235K in 2021.
* Leading developmental and epileptic encephalopathy companies working in the treatment market are Takeda, Eisai, SK Life Science, Stoke Therapeutics, Harmony Biosciences/Epygenix, Longboard Pharmaceuticals, Praxis Precision Medicines, Neurocrine Biosciences, Bright Minds Biosciences, Cerecin, Encoded Therapeutics, Bloom Science, IAMA Therapeutics, Ultragenyx Pharmaceutical, Neuroene Therapeutics, Regel Therapeutics, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Ovid Therapeutics, BioPharm Solutions and others.
* The promising developmental and epileptic encephalopathy therapies in the pipeline include EPX-100, EPX-200, EPX-300, XEN 496, LP 352, STK-001, JBPOS0101, Soticlestat (OV935/TAK-935), Carisbamate, NBI-921352, NBI-827104, PRAX-562, and others.
* The current therapeutic landscape of DEE in the United States is driven by current treatment practices which includes anti-epileptic drugs (AEDs), Epidiolex/Epidyolex (cannabidiol), Fintepla (Fenfluramine), Afinitor/Votubia (Everolimus), and others.

Discover which therapies are expected to grab the major developmental and epileptic encephalopathy market share @ Developmental and Epileptic Encephalopathy Market Forecast [https://www.delveinsight.com/report-store/developmental-and-epileptic-encephalopathies-dee-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Developmental and Epileptic Encephalopathy Overview

Developmental and epileptic encephalopathy is a seizure disorder characterized by infantile spasms, a type of seizure. Spasms typically appear before the age of one. The prognosis for developmental and epileptic encephalopathy is bleak. This rare disease, typically described as progressive and incurable, is also associated with severe physical and cognitive disabilities and unexplained death.

The most common cause of epileptic encephalopathy in childhood is structural abnormalities, which can be congenital (such as cortical malformations) or acquired (such as hypoxic-ischemic after the EEG often evolves to atypical hypsarrhythmia, which is a transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.

Developmental and Epileptic Encephalopathy Epidemiology Segmentation

DelveInsight estimates that there were approximately 235K diagnosed prevalent cases of DEE in the 7MM in 2021.

Among the EU-4 countries, the diagnosed prevalent population of DEE was maximum in Germany in 2021.

The developmental and epileptic encephalopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Diagnosed Prevalent Population of developmental and epileptic encephalopathy
* Treated pool of developmental and epileptic encephalopathy

Download the report to understand which factors are driving developmental and epileptic encephalopathy epidemiology trends @ https://www.delveinsight.com/report-store/developmental-and-epileptic-encephalopathies-dee-market [https://www.delveinsight.com/report-store/developmental-and-epileptic-encephalopathies-dee-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Developmental and Epileptic Encephalopathy Treatment Market

Some of the general principles and approach to pediatric epilepsy treatment can be found in the epileptic encephalopathy treatment. The best anti-epileptic treatment is chosen based on the type of epilepsy syndrome. Although anti-seizure medications are commonly used, some types of seizures are notoriously difficult to control. It is the primary method of controlling epileptic seizures and is almost always the first class of therapy medications.

Some of the FDA-approved drugs used for DEE treatment include Epidiolex (Jazz Pharmaceuticals), Diacomit (Biocodex), Fintepla (Zogenix), Sabril (Lundbeck), Ztalmy (Marinus Pharmaceuticals), Afinitor Disperz/Votubia (Novartis), Sympazan (Aquestive Therapeutics), Trokendi XR (Supernus Pharmaceuticals), Onfi (Lundbeck), Banzel (Eisai Pharmaceuticals), Lamictal (GlaxoSmithKline), and others.

In some children, steroid therapy with adrenocorticotropic hormone (ACTH) or prednisone has been beneficial. When medications do not work well, a vagus nerve stimulator or the ketogenic diet may be considered in patients. Moreover, in children with seizures that begin in one area or involve only one side of the brain, epilepsy surgery may be an option. In these cases, a focal resection (removal of a single area) or a hemispherectomy (removal of the majority of one side of the brain) may be considered.

To know more about developmental and epileptic encephalopathy treatment options, visit @ Developmental and Epileptic Encephalopathy Treatment Market [https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Developmental and Epileptic Encephalopathy Pipeline Therapies and Key Companies

* XEN496: Xenon Pharmaceuticals
* Soticlestat: Takeda/Ovid Therapeutics
* Carisbamate: SK Life Science
* EPX-100 (Clemizole HCl): Epygenix
* NBI-921352: Neurocrine Biosciences
* STK-001: Stoke Therapeutics
* NBI-827104: Neurocrine Biosciences
* JBPOS0101: BioPharm Solutions
* PRAX-562: Praxis Precision Medicines
* EPX-200 (Lorcaserin): Epygenix
* EPX-300: Epygenix
* LP352: Longboard Pharmaceuticals

Learn more about the DEE FDA-approved drugs @ Developmental and Epileptic Encephalopathy Drugs Market [https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Developmental and Epileptic Encephalopathy Market Dynamics

The dynamics of developmental and epileptic encephalopathy market is anticipated to change in the coming years. Ztalmy, the first licensed therapy for CDKL5 deficiency disorder, was recently approved in the United States, boosting the developmental and epileptic encephalopathy market growth. Moreover, the void left by a lack of licensed medications will be filled by further R&D advancement. In addition, Epidiolex and Fintepla continue to add new prescribers and expand their existing prescriber base due to their strong uptake.

Furthermore, the current competitive scenario for DEE is limited to a few therapies. Currently, the DEE market appears to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to capture the potential developmental and epileptic encephalopathy market space. Emerging drugs with improved seizure control may positively impact the developmental and epileptic encephalopathy market landscape and patients' quality of life.

However, several factors are impeding the growth of the DEE market. Rare epileptic syndromes, such as LGS, Dravet Syndrome, and CDKL5 deficiency disorder, are extremely complex and heterogeneous diseases with multiple etiologies, posing several diagnostic challenges as the disease progresses.

Scope of the Developmental and Epileptic Encephalopathy Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
* Base Year: 2021
* Developmental and Epileptic Encephalopathy Market CAGR: 15.5%
* Developmental and Epileptic Encephalopathy Market Size in 2021: USD 1,371 million

* Key Developmental and Epileptic Encephalopathy Companies: Takeda, Eisai, SK Life Science, Stoke Therapeutics, Harmony Biosciences/Epygenix, Longboard Pharmaceuticals, Praxis Precision Medicines, Neurocrine Biosciences, Bright Minds Biosciences, Cerecin, Encoded Therapeutics, Bloom Science, IAMA Therapeutics, Ultragenyx Pharmaceutical, Neuroene Therapeutics, Regel Therapeutics, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Ovid Therapeutics, BioPharm Solutions and others.

* Key Developmental and Epileptic Encephalopathy Therapies: XEN496, Soticlestat, Carisbamate, Carisbamate, EPX-100, NBI-921352, STK-001, NBI-827104, JBPOS0101, PRAX-562, EPX-200 (Lorcaserin), EPX-300, LP352, and others
* Therapeutic Assessment: Developmental and Epileptic Encephalopathy current marketed and emerging therapies
* Developmental and Epileptic Encephalopathy Market Dynamics: Developmental and Epileptic Encephalopathy market drivers and barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Unmet Needs, KOL's views, Analyst's views, Developmental and Epileptic Encephalopathy Market Access and Reimbursement

Discover more about DEE drugsin development @ Developmental and Epileptic Encephalopathy Clinical Trials [https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1

Key Insights

2

Developmental and Epileptic Encephalopathy Report Introduction

3

Executive Summary

4

Key Events

5

Developmental and Epileptic Encephalopathy SWOT Analysis

6

Developmental and Epileptic Encephalopathy Epidemiology and Market Methodology

7

Developmental and Epileptic Encephalopathy (DEE) Market Overview at a Glance

7.1

Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2021

7.2

Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2034

8

Developmental and Epileptic Encephalopathy Background and Overview

8.1

West Syndrome

8.2

Dravet Syndrome

8.3

Lennox-Gastaut Syndrome

8.4

Landau-Kleffner Syndrome (LKS) (Acquired Epileptic Aphasia)

8.5

Epilepsy with Continuous Spike-and-Waves during Slow-Wave Sleep

8.6

Doose Syndrome (myoclonic atonic epilepsy)

8.7

CDKL5 deficiency disorder (CDD)

8.8

Tuberous sclerosis complex (TSC)

8.9

Genetic Epilepsy

8.10

Biomarkers of epileptic encephalopathies

9

Treatment of Developmental and Epileptic Encephalopathy

9.1

Antiseizure medications

9.2

Steroid therapy

9.3

Other Therapies

9.4

Epilepsy surgery

9.5

Developmental and Epileptic Encephalopathy Treatment Algorithm

10

Developmental and Epileptic Encephalopathy Treatment Guidelines

11

Developmental and Epileptic Encephalopathy Epidemiology and Patient Population of 7MM

11.1

Key Findings

11.2

Assumptions and Rationale

11.2.1

Dravet Syndrome

11.2.2

Lennox-Gastaut Syndrome

11.2.3

Ohtahara Syndrome

11.2.4

West Syndrome

11.2.5

Landau-Kleffner Syndrome

11.2.6

Tuberous Sclerosis Complex

11.2.7

CDKL5 deficiency disorder

11.2.8

Others

11.3

Diagnosed Prevalent Population of DEE in 7MM

11.4

United States

11.4.1

Diagnosed Prevalent Population of DEE in the United States

11.5

EU-4 and UK

11.5.1

Diagnosed Prevalence of DEE in the EU-4 and the UK

11.6

Japan

11.6.1

Diagnosed Prevalent Population of Developmental and Epileptic Encephalopathy in Japan

12

Marketed Developmental and Epileptic Encephalopathy Drugs

12.1

Key Competitor

13

Emerging Developmental and Epileptic Encephalopathy Drugs

13.1

Key Competitors

14

Developmental and Epileptic Encephalopathy (DEE): 7MM Market Analysis

14.1

Key Findings

14.2

Developmental and Epileptic Encephalopathy Market Outlook

14.3

Key Market Forecast Assumptions

14.4

Attribute Analysis

14.5

Total Market Size of Developmental and Epileptic Encephalopathy in the 7MM

14.6

Developmental and Epileptic Encephalopathy Market Size by Current and Emerging Therapies in the 7MM

14.7

United States Market Size

14.7.1

Total Market Size of DEE in the United States

14.7.2

Market Size of DEE by Current and Emerging Therapies in the United States

14.8

EU-4 and UK Market Size

14.8.1

Total Market size of DEE in the EU-4 and the UK

14.8.2

Market Size of DEE by Current and Emerging Therapies in EU-4 and the UK

14.9

Japan

14.9.1

Total Market size of DEE in Japan

14.9.2

Market Size of DEE by Current and Emerging Therapies in Japan

15

Developmental and Epileptic Encephalopathy Market Drivers

16

Developmental and Epileptic Encephalopathy Market Barriers

17

Developmental and Epileptic Encephalopathy Unmet Needs

18

Developmental and Epileptic Encephalopathy Market Access and Reimbursement

19

Appendix

19.1

Bibliography

19.2

Report Methodology

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=developmental-and-epileptic-encephalopathies-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-medication-therapies-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting



This release was published on openPR.